Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
69 hedge funds and large institutions have $94.1M invested in Aevi Genomic Medicine Inc in 2016 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 15 reducing their positions, and 2 closing their positions.
650% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 2
73% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 15
59% more capital invested
Capital invested by funds: $59.4M → $94.1M (+$34.8M)
23% more funds holding
Funds holding: 56 → 69 (+13)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.46M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.36M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.06M |
| 4 |
BC
Broadfin Capital
New York
|
+$1.71M |
| 5 |
PA
Perceptive Advisors
New York
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$239K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$193K |
| 3 |
AA
ALPS Advisors
Denver,
Colorado
|
-$163K |
| 4 |
QF
QVT Financial
New York
|
-$98.8K |
| 5 |
Citigroup
New York
|
-$96.2K |
GNMX Hedge Fund Activity: Q2 2016 in Review
69 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q2 2016, worth a combined $94.1M — up 59% from $59.4M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new GNMX positions and 2 closed out — a net gain of 13 holders — while 26 added to existing stakes and 15 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $4.46M. The largest seller was LPL Financial, cutting an estimated $239K.
- 69 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q2 2016, up from 56 in Q1 2016.
- Funds reported $94.1M of Aevi Genomic Medicine Inc stock for Q2 2016, up 59% quarter-over-quarter.
- 15 funds opened new Aevi Genomic Medicine Inc positions in Q2 2016 and 2 closed out, a net change of +13 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q2 2016 was Adage Capital Partners, an estimated $4.46M added.
- The largest Aevi Genomic Medicine Inc seller in Q2 2016 was LPL Financial, an estimated $239K sold.
Based on aggregated 13F filings for Q2 2016.